Welcome to our dedicated page for Alexion Pharms news (Ticker: ALXN), a resource for investors and traders seeking the latest updates and insights on Alexion Pharms stock.
Alexion Pharmaceuticals, Inc. (ALXN) generates frequent news flow related to rare diseases, complement inhibition and ultra-rare metabolic disorders. As a global biopharmaceutical company focused on the discovery, development and commercialization of medicines for devastating conditions, Alexion regularly reports clinical data, regulatory milestones and corporate developments that are relevant to investors, clinicians and patients.
News about Alexion often highlights results from clinical trials of its complement inhibitors in diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG). The company has announced Phase 3 data showing statistically significant improvements in patient-reported and physician-assessed outcomes in gMG, as well as long-term safety and efficacy findings in PNH. Updates from major scientific meetings, including the European Hematology Association Congress and the American Academy of Neurology annual meeting, provide additional detail on how these therapies perform in both clinical trial and real-world settings.
Alexion’s news flow also covers enzyme replacement therapies for hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D), and the use of a Factor Xa inhibitor reversal agent in acute care. Pipeline updates describe progress on mid-to-late-stage programs such as a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and oral Factor D inhibitors, as well as early-stage work in conditions like light chain (AL) amyloidosis.
Corporate announcements, including the definitive agreement for AstraZeneca to acquire Alexion, add another dimension to the news landscape. Readers following ALXN news can expect coverage of clinical trial readouts, regulatory decisions, collaborations, scientific presentations and transaction-related updates. This mix of medical, scientific and corporate information helps market participants understand how Alexion’s rare disease portfolio and pipeline are evolving over time.
Alexion Pharmaceuticals (NASDAQ: ALXN) announced three accepted abstracts for presentation at the 73rd annual American Academy of Neurology meeting from April 17-22, 2021. The abstracts focus on real-world data for SOLIRIS (eculizumab), highlighting its effectiveness in reducing myasthenic crises and hospitalizations related to generalized myasthenia gravis (gMG). Additionally, long-term efficacy data for neuromyelitis optica spectrum disorder (NMOSD) will be shared, including results from the Phase 3 PREVENT trial. The meeting will be held virtually with accessible posters throughout the event.
Alexion Pharmaceuticals reported 2020 financial results, with total revenues reaching $6.069 billion, a 22% rise from 2019. However, GAAP diluted EPS decreased to $2.72 from $10.70 due to $2.053 billion in impairment charges linked to KANUMA. Non-GAAP diluted EPS grew by 19% to $12.51. Total revenues for Q4 were $1.592 billion, up 15% year-over-year. While SOLIRIS and ULTOMIRIS sales increased, KANUMA saw a 14% decline. The company highlighted ongoing clinical trials and a strong pipeline with over 20 development programs.
Alexion Pharmaceuticals (Nasdaq: ALXN) will announce its financial results for Q4 and full year 2020 on February 4, 2021. Due to its acquisition by AstraZeneca, no conference call will be held. The acquisition deal, valued at $39 billion, offers Alexion shareholders $60 in cash and 2.1243 AstraZeneca ADS per share, equating to $175 per share based on AstraZeneca’s stock price at the announcement. The transaction aims to enhance both companies' capabilities in developing medicines and is expected to close in Q3 2021, pending regulatory approvals.
Alexion Pharmaceuticals (NASDAQ: ALXN) has announced a pause in enrollment for its Phase 3 study of ULTOMIRIS in adults with severe COVID-19 on mechanical ventilation, following an independent data monitoring committee's recommendation. The interim analysis showed a lack of efficacy when ULTOMIRIS was added to best supportive care. While patients already enrolled will continue in the study, Alexion plans to analyze the data to identify potential benefit for specific subgroups. The company remains dedicated to the rare disease community and ongoing development of ULTOMIRIS.
Alexion Pharmaceuticals (NASDAQ:ALXN) has achieved significant commercial, clinical, and financial milestones, presenting its strategy at the 39th Annual J.P. Morgan Healthcare Conference. The company targets $9 to $10 billion in revenue by 2025, driven by growth in its neurology franchise and new product launches. Alexion continues to build its innovative pipeline with over 20 programs. The acquisition by AstraZeneca, set to finalize in Q3 2021, promises to enhance its market position and create value for shareholders. The company expects to exceed 2020 revenue guidance of $5.9 to $5.95 billion.
Alexion Pharmaceuticals (Nasdaq: ALXN) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 12 at 7:30 a.m. ET. The event will feature management insights and updates on the company's strategic initiatives.
Live audio webcasts can be accessed at http://ir.alexion.com, and archived versions will be available on the company’s website shortly after the presentation.
AstraZeneca has reached a definitive agreement to acquire Alexion Pharmaceuticals for approximately $39 billion, translating to $175 per share for Alexion shareholders. The deal comprises $60 in cash and 2.1243 AstraZeneca ADSs per Alexion share, representing a premium of 45% over Alexion's closing stock price prior to the announcement. This acquisition, approved by both companies' boards, is anticipated to close in Q3 2021, pending regulatory and shareholder approvals. AstraZeneca aims to enhance its immunology portfolio and leverage Alexion's expertise in rare diseases.
Alexion Pharmaceuticals (NASDAQ:ALXN) announces the European Commission's approval of ULTOMIRIS® 100 mg/mL for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). This long-acting C5 inhibitor reduces average annual infusion times by approximately 60%, lowering treatment time to six hours or less per year. The approval is based on a comprehensive clinical data set confirming comparable safety and efficacy to the original formulation. ULTOMIRIS 100 mg/mL aligns with Alexion's commitment to improve patient quality of life and reduce healthcare burdens.
Alexion Pharmaceuticals (Nasdaq:ALXN) announced its participation in two upcoming investor conferences. The Stifel 2020 Virtual Healthcare Conference will be held on November 17, 2020, from 10:00-10:30 a.m. ET. Additionally, the 3rd Annual Evercore ISI HealthCONx Conference is scheduled for December 1, 2020, from 8:50-9:35 a.m. ET. Live audio webcasts will be accessible on the Alexion investor website, with archived versions available for a limited time after each event.
Caelum Biosciences and Alexion Pharmaceuticals (NASDAQ: ALXN) announced two accepted abstracts for the 62nd American Society of Hematology (ASH) Annual Meeting. Presentations will focus on CAEL-101, an amyloid fibril-targeted therapy, showcasing its safety and efficacy in AL amyloidosis patients. The Phase 2 study indicates promising early organ response. The CARES Phase 3 program is also underway, enrolling approximately 370 patients globally. CAEL-101 aims to improve organ function by targeting amyloid deposits, having received Orphan Drug Designation from the FDA and EMA.